Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EXT608 in Human Healthy Adults; A First-in-Human, Randomized, Double-Blind, Placebo-controlled, Single Dose Escalation Study

NCT05408663 is registered in ClinicalTrials.gov with Extend Biosciences Inc. as lead sponsor.

NCT NCT05408663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05408663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EXT608 in Human Healthy Adults; A First-in-Human, Randomized, Double-Blind, Placebo-controlled, Single Dose Escalation Study
Lead sponsor
Extend Biosciences Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 21, 2022
Completion date
June 13, 2023
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

safety issues